Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib +/- Vinblastine in Recurrent/Progressive Low-Grade Gliomas
NCT04576117Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of selumetinib, vinblastine in glioma, sponsored by National Cancer Institute. Started Feb 2021; status: active, not recruiting.
02
Drugs
selumetinibvinblastine
03
Conditions
glioma
Beyond the preview
Go deeper on NCT04576117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04576117.